Aberdeen Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Aberdeen Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$3.24M	Hold	97,400	–	–	0.01%	540
2017 Q1	$3.13M	Sell	97,400 -22,000	-18%	-$751K	0.01%	527
2016 Q4	$4.33M	Hold	119,400	–	–	0.02%	460
2016 Q3	$5.49M	Hold	119,400	–	–	0.02%	421
2016 Q2	$6M	Hold	119,400	–	–	0.02%	393
2016 Q1	$6.39M	Sell	119,400 -2,100	-2%	-$123K	0.02%	374
2015 Q4	$6.8M	Hold	121,500	–	–	0.02%	368
2015 Q3	$6.86M	Sell	121,500 -18,397	-13%	-$1.19M	0.02%	324
2015 Q2	$8.27M	Hold	139,897	–	–	0.02%	304
2015 Q1	$8.72M	Sell	139,897 -75,982	-35%	-$4.42M	0.02%	276
2014 Q4	$12.4M	Sell	215,879 -160,820	-43%	-$8.96M	0.03%	241
2014 Q3	$20.2M	Sell	376,699 -25,200	-6%	-$1.34M	0.04%	207
2014 Q2	$21.1M	Buy	401,899 +68,982	+21%	+$3.53M	0.04%	213
2014 Q1	$17.6M	Hold	332,917	–	–	0.05%	104
2013 Q4	$13.3M	Buy	332,917 +13,000	+4%	+$512K	0.04%	116
2013 Q3	$12.1M	Buy	319,917 +10,000	+3%	+$390K	0.03%	112
2013 Q2	$12.1M	Buy	+309,917	New	+$12.1M	0.04%	103

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aberdeen Asset Management's TEVA Position: Q2 2017 in Review

Aberdeen Asset Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2017 at 97,400 shares worth $3.24M. The position accounts for 0.01% of the portfolio, ranked #540.

Aberdeen Asset Management first reported a position in TEVA in Q2 2013 and has held it in 17 quarters since. The position peaked at $21.1M in Q2 2014. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Aberdeen Asset Management held 97,400 shares of Teva Pharmaceuticals worth $3.24M as of Q2 2017.
Aberdeen Asset Management left its Teva Pharmaceuticals share count unchanged in Q2 2017.
Teva Pharmaceuticals made up 0.01% of Aberdeen Asset Management's portfolio in Q2 2017, its #540 holding.
Aberdeen Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Aberdeen Asset Management's Teva Pharmaceuticals position peaked at $21.1M in Q2 2014.
649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.